Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04299321Completed

Retrospective Natural History Study of Infants and Toddlers With LAMA2-CMD

Role: collaborator

NCT01403402Recruiting

Congenital Muscle Disease Study of Patient and Family Reported Medical Information

Role: lead

NCT01840657Completed

Myotubular Myopathy Event Study

Role: lead

NCT01817946Completed

Myotubular Myopathy Genetic Testing Study

Role: lead

NCT01952028Withdrawn

LAMA2-related Muscular Dystrophy Brain Study

Role: lead

NCT01836627Not ApplicableCompleted

A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy

Role: collaborator

All 6 trials loaded